| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 59 | 2025 | 98 | 22.760 |
Why?
|
| Immunologic Factors | 18 | 2026 | 35 | 7.390 |
Why?
|
| Rituximab | 17 | 2026 | 20 | 5.590 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 16 | 2026 | 19 | 5.490 |
Why?
|
| Breast Feeding | 13 | 2020 | 112 | 4.040 |
Why?
|
| Pregnancy Complications | 14 | 2020 | 202 | 3.200 |
Why?
|
| Humans | 96 | 2026 | 16832 | 3.080 |
Why?
|
| Female | 73 | 2026 | 12193 | 2.610 |
Why?
|
| Adult | 52 | 2026 | 7255 | 2.380 |
Why?
|
| Male | 47 | 2026 | 9556 | 2.010 |
Why?
|
| Disease Progression | 6 | 2026 | 252 | 1.990 |
Why?
|
| Vitamin D | 5 | 2018 | 75 | 1.970 |
Why?
|
| Retrospective Studies | 21 | 2026 | 2463 | 1.920 |
Why?
|
| Postpartum Period | 8 | 2023 | 89 | 1.920 |
Why?
|
| Neurology | 4 | 2021 | 4 | 1.870 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 2 | 2026 | 2 | 1.800 |
Why?
|
| Vitamin D Deficiency | 4 | 2018 | 23 | 1.760 |
Why?
|
| Middle Aged | 33 | 2026 | 7515 | 1.690 |
Why?
|
| Pregnancy | 22 | 2023 | 1555 | 1.460 |
Why?
|
| Young Adult | 20 | 2026 | 2456 | 1.410 |
Why?
|
| Recurrence | 9 | 2023 | 149 | 1.400 |
Why?
|
| Immunosuppressive Agents | 6 | 2023 | 14 | 1.160 |
Why?
|
| Hispanic Americans | 7 | 2019 | 350 | 1.140 |
Why?
|
| Sunlight | 2 | 2018 | 13 | 1.080 |
Why?
|
| Abnormalities, Drug-Induced | 4 | 2016 | 15 | 1.070 |
Why?
|
| Natalizumab | 10 | 2023 | 10 | 1.070 |
Why?
|
| Cohort Studies | 16 | 2026 | 2396 | 1.050 |
Why?
|
| Glatiramer Acetate | 6 | 2020 | 6 | 1.050 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2022 | 66 | 1.040 |
Why?
|
| Registries | 10 | 2023 | 449 | 1.010 |
Why?
|
| Immunotherapy | 2 | 2026 | 7 | 1.010 |
Why?
|
| Interferon-beta | 6 | 2020 | 6 | 1.010 |
Why?
|
| Ethnic Groups | 4 | 2014 | 418 | 1.000 |
Why?
|
| California | 14 | 2026 | 2244 | 0.980 |
Why?
|
| Antibodies, Monoclonal | 6 | 2020 | 24 | 0.980 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2020 | 23 | 0.950 |
Why?
|
| Algorithms | 3 | 2025 | 210 | 0.940 |
Why?
|
| Prodromal Symptoms | 1 | 2025 | 3 | 0.880 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 2 | 2015 | 7 | 0.880 |
Why?
|
| Neuromyelitis Optica | 2 | 2021 | 2 | 0.870 |
Why?
|
| Migraine Disorders | 1 | 2025 | 17 | 0.860 |
Why?
|
| Hepatitis B Vaccines | 2 | 2015 | 44 | 0.850 |
Why?
|
| Phenotype | 1 | 2024 | 105 | 0.850 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2024 | 319 | 0.840 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2022 | 10 | 0.830 |
Why?
|
| Agammaglobulinemia | 1 | 2024 | 2 | 0.830 |
Why?
|
| Drugs, Essential | 1 | 2023 | 1 | 0.820 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2023 | 1 | 0.820 |
Why?
|
| Health Status Disparities | 2 | 2024 | 145 | 0.810 |
Why?
|
| Fingolimod Hydrochloride | 5 | 2023 | 5 | 0.810 |
Why?
|
| Adolescent | 14 | 2026 | 3464 | 0.810 |
Why?
|
| Disabled Persons | 2 | 2015 | 33 | 0.810 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2020 | 27 | 0.790 |
Why?
|
| Papillomavirus Vaccines | 2 | 2015 | 113 | 0.790 |
Why?
|
| Risk Factors | 11 | 2025 | 3108 | 0.770 |
Why?
|
| Family | 1 | 2024 | 99 | 0.760 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 213 | 0.760 |
Why?
|
| Pseudotumor Cerebri | 2 | 2013 | 3 | 0.750 |
Why?
|
| Obesity | 3 | 2013 | 811 | 0.730 |
Why?
|
| Demyelinating Diseases | 2 | 2013 | 4 | 0.730 |
Why?
|
| Vaccination | 3 | 2022 | 725 | 0.720 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2020 | 34 | 0.720 |
Why?
|
| Incidence | 10 | 2024 | 1229 | 0.720 |
Why?
|
| Pregnancy Outcome | 3 | 2023 | 160 | 0.710 |
Why?
|
| Vaccines | 2 | 2015 | 225 | 0.710 |
Why?
|
| Access to Information | 1 | 2021 | 11 | 0.700 |
Why?
|
| Awards and Prizes | 1 | 2021 | 9 | 0.680 |
Why?
|
| Cytokines | 2 | 2020 | 28 | 0.680 |
Why?
|
| Case-Control Studies | 8 | 2025 | 995 | 0.670 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 39 | 0.670 |
Why?
|
| Withholding Treatment | 1 | 2021 | 26 | 0.660 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2026 | 107 | 0.630 |
Why?
|
| Nervous System Diseases | 3 | 2019 | 15 | 0.630 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.620 |
Why?
|
| Cognition Disorders | 1 | 2020 | 30 | 0.610 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.600 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 56 | 0.600 |
Why?
|
| Gene-Environment Interaction | 1 | 2019 | 21 | 0.600 |
Why?
|
| Quality Improvement | 1 | 2021 | 184 | 0.590 |
Why?
|
| Risk | 6 | 2017 | 453 | 0.590 |
Why?
|
| Treatment Outcome | 5 | 2026 | 1098 | 0.570 |
Why?
|
| Environmental Exposure | 1 | 2019 | 120 | 0.560 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 262 | 0.560 |
Why?
|
| Immunoglobulin G | 3 | 2024 | 33 | 0.540 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2018 | 4 | 0.540 |
Why?
|
| African Continental Ancestry Group | 2 | 2018 | 117 | 0.540 |
Why?
|
| United States | 10 | 2023 | 3858 | 0.540 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 60 | 0.530 |
Why?
|
| Herpesvirus 4, Human | 1 | 2017 | 6 | 0.530 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 3 | 0.530 |
Why?
|
| Child | 10 | 2023 | 2433 | 0.520 |
Why?
|
| Antibodies, Viral | 1 | 2017 | 70 | 0.500 |
Why?
|
| Medication Reconciliation | 2 | 2013 | 6 | 0.480 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2016 | 5 | 0.480 |
Why?
|
| Estriol | 1 | 2015 | 2 | 0.470 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2006 | 2 | 0.470 |
Why?
|
| Prevalence | 7 | 2023 | 785 | 0.460 |
Why?
|
| Peptides | 2 | 2014 | 14 | 0.460 |
Why?
|
| Disease Management | 2 | 2013 | 106 | 0.460 |
Why?
|
| Emigration and Immigration | 1 | 2015 | 14 | 0.440 |
Why?
|
| Crotonates | 1 | 2014 | 1 | 0.430 |
Why?
|
| Toluidines | 1 | 2014 | 1 | 0.430 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1233 | 0.430 |
Why?
|
| Continental Population Groups | 2 | 2013 | 255 | 0.420 |
Why?
|
| Aged | 11 | 2024 | 5901 | 0.410 |
Why?
|
| Propylene Glycols | 1 | 2014 | 1 | 0.410 |
Why?
|
| Sphingosine | 1 | 2014 | 1 | 0.410 |
Why?
|
| Premature Birth | 4 | 2023 | 133 | 0.410 |
Why?
|
| Spinal Cord Injuries | 1 | 2013 | 4 | 0.400 |
Why?
|
| Hospital Mortality | 3 | 2022 | 134 | 0.400 |
Why?
|
| Residence Characteristics | 2 | 2015 | 244 | 0.390 |
Why?
|
| Hospitalization | 4 | 2022 | 816 | 0.390 |
Why?
|
| Academies and Institutes | 2 | 2023 | 4 | 0.380 |
Why?
|
| Logistic Models | 3 | 2025 | 796 | 0.370 |
Why?
|
| Interferon-gamma | 3 | 2010 | 7 | 0.370 |
Why?
|
| Follow-Up Studies | 4 | 2026 | 1058 | 0.360 |
Why?
|
| Prospective Studies | 6 | 2020 | 1186 | 0.350 |
Why?
|
| European Continental Ancestry Group | 4 | 2019 | 400 | 0.350 |
Why?
|
| Dietary Supplements | 3 | 2018 | 83 | 0.350 |
Why?
|
| T-Lymphocytes | 2 | 2010 | 7 | 0.350 |
Why?
|
| Puerperal Disorders | 2 | 2020 | 7 | 0.340 |
Why?
|
| Infant, Newborn | 8 | 2023 | 828 | 0.340 |
Why?
|
| Milk, Human | 2 | 2020 | 9 | 0.320 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 19 | 0.310 |
Why?
|
| Infant | 6 | 2024 | 1212 | 0.310 |
Why?
|
| Immune Tolerance | 1 | 2010 | 5 | 0.310 |
Why?
|
| Pregnancy Trimesters | 1 | 2010 | 27 | 0.310 |
Why?
|
| Clinical Trials as Topic | 3 | 2012 | 114 | 0.300 |
Why?
|
| Diet | 2 | 2022 | 349 | 0.300 |
Why?
|
| Socioeconomic Factors | 3 | 2017 | 571 | 0.300 |
Why?
|
| Aquaporin 4 | 1 | 2009 | 2 | 0.300 |
Why?
|
| Patient Selection | 2 | 2012 | 175 | 0.300 |
Why?
|
| Age Factors | 3 | 2020 | 814 | 0.300 |
Why?
|
| Time Factors | 4 | 2020 | 989 | 0.300 |
Why?
|
| African Americans | 3 | 2021 | 394 | 0.290 |
Why?
|
| JC Virus | 2 | 2006 | 2 | 0.290 |
Why?
|
| Integrin alpha4 | 2 | 2006 | 2 | 0.290 |
Why?
|
| HLA-DRB1 Chains | 2 | 2019 | 12 | 0.280 |
Why?
|
| Drug Administration Schedule | 2 | 2025 | 94 | 0.270 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 3 | 2002 | 3 | 0.270 |
Why?
|
| Prognosis | 3 | 2021 | 568 | 0.260 |
Why?
|
| Cyclophosphamide | 1 | 2026 | 2 | 0.240 |
Why?
|
| Disability Evaluation | 3 | 2015 | 38 | 0.240 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2006 | 2 | 0.240 |
Why?
|
| Child, Preschool | 5 | 2014 | 1430 | 0.240 |
Why?
|
| Lactation | 2 | 2020 | 37 | 0.230 |
Why?
|
| Longitudinal Studies | 3 | 2013 | 653 | 0.230 |
Why?
|
| Abortion, Spontaneous | 2 | 2016 | 49 | 0.230 |
Why?
|
| Opportunistic Infections | 1 | 2005 | 6 | 0.230 |
Why?
|
| Teratoma | 1 | 2024 | 1 | 0.210 |
Why?
|
| Sweden | 5 | 2021 | 17 | 0.200 |
Why?
|
| Ovarian Neoplasms | 1 | 2024 | 53 | 0.200 |
Why?
|
| Cognitive Dysfunction | 1 | 2024 | 61 | 0.200 |
Why?
|
| Respiratory Insufficiency | 1 | 2023 | 16 | 0.190 |
Why?
|
| Noninvasive Ventilation | 1 | 2023 | 11 | 0.190 |
Why?
|
| Blindness | 1 | 2022 | 3 | 0.190 |
Why?
|
| Sex Factors | 2 | 2020 | 560 | 0.190 |
Why?
|
| Dexamethasone | 1 | 2022 | 10 | 0.190 |
Why?
|
| Infusions, Intravenous | 2 | 2021 | 9 | 0.190 |
Why?
|
| Pregnancy, Animal | 1 | 2002 | 1 | 0.190 |
Why?
|
| Suppressor Factors, Immunologic | 1 | 2002 | 1 | 0.190 |
Why?
|
| Food | 1 | 2022 | 36 | 0.180 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 1204 | 0.180 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2019 | 5 | 0.180 |
Why?
|
| Risk Assessment | 2 | 2021 | 1047 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2011 | 3 | 0.180 |
Why?
|
| Bibliometrics | 1 | 2021 | 2 | 0.180 |
Why?
|
| Medical Records | 2 | 2019 | 85 | 0.180 |
Why?
|
| Pandemics | 2 | 2022 | 289 | 0.180 |
Why?
|
| Alleles | 2 | 2019 | 59 | 0.170 |
Why?
|
| Educational Status | 2 | 2020 | 163 | 0.170 |
Why?
|
| Body Mass Index | 2 | 2018 | 925 | 0.170 |
Why?
|
| Leadership | 1 | 2021 | 34 | 0.170 |
Why?
|
| Seasons | 2 | 2012 | 114 | 0.170 |
Why?
|
| Brain | 3 | 2013 | 47 | 0.170 |
Why?
|
| Diet Surveys | 1 | 2021 | 56 | 0.160 |
Why?
|
| Disease Susceptibility | 2 | 2016 | 36 | 0.160 |
Why?
|
| Fruit | 1 | 2021 | 79 | 0.160 |
Why?
|
| Early Medical Intervention | 1 | 2020 | 11 | 0.160 |
Why?
|
| Verbal Behavior | 1 | 2020 | 2 | 0.160 |
Why?
|
| Psychomotor Performance | 1 | 2020 | 4 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 305 | 0.160 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 410 | 0.150 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 47 | 0.150 |
Why?
|
| Feeding Behavior | 1 | 2021 | 161 | 0.150 |
Why?
|
| Chronic Disease | 2 | 2021 | 382 | 0.150 |
Why?
|
| Child Development | 1 | 2020 | 58 | 0.150 |
Why?
|
| Family Planning Services | 1 | 2019 | 20 | 0.150 |
Why?
|
| Secondary Prevention | 2 | 2014 | 44 | 0.150 |
Why?
|
| Pharmacoepidemiology | 1 | 2019 | 15 | 0.150 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2020 | 22 | 0.150 |
Why?
|
| Transcription Factors | 1 | 2019 | 15 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2024 | 693 | 0.140 |
Why?
|
| Models, Theoretical | 1 | 2019 | 66 | 0.140 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2018 | 3 | 0.140 |
Why?
|
| Ultraviolet Rays | 1 | 2018 | 6 | 0.140 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 24 | 0.140 |
Why?
|
| Genotype | 1 | 2018 | 198 | 0.130 |
Why?
|
| Hygiene | 1 | 2017 | 2 | 0.130 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2017 | 2 | 0.130 |
Why?
|
| Regression Analysis | 2 | 2019 | 261 | 0.130 |
Why?
|
| Reproductive Physiological Phenomena | 1 | 2017 | 3 | 0.130 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2020 | 206 | 0.130 |
Why?
|
| Emigrants and Immigrants | 1 | 2017 | 26 | 0.130 |
Why?
|
| Smoking | 1 | 2019 | 373 | 0.130 |
Why?
|
| Analysis of Variance | 2 | 2015 | 120 | 0.120 |
Why?
|
| Progestins | 1 | 2016 | 24 | 0.120 |
Why?
|
| Societies, Medical | 2 | 2013 | 67 | 0.120 |
Why?
|
| Body Height | 1 | 2016 | 54 | 0.120 |
Why?
|
| Cesarean Section | 1 | 2016 | 34 | 0.120 |
Why?
|
| Pregnancy Trimester, First | 1 | 2016 | 45 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2019 | 294 | 0.110 |
Why?
|
| Neoplasms | 1 | 2020 | 447 | 0.110 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2014 | 2 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2014 | 8 | 0.100 |
Why?
|
| Crohn Disease | 1 | 2014 | 12 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 45 | 0.100 |
Why?
|
| Prepaid Health Plans | 1 | 2013 | 16 | 0.100 |
Why?
|
| B-Lymphocytes | 2 | 2011 | 5 | 0.090 |
Why?
|
| Animals | 4 | 2014 | 237 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2010 | 569 | 0.090 |
Why?
|
| Censuses | 1 | 2012 | 30 | 0.090 |
Why?
|
| Hydroxycholecalciferols | 1 | 2010 | 1 | 0.080 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2010 | 3 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2002 | 29 | 0.080 |
Why?
|
| Birth Certificates | 1 | 2010 | 24 | 0.080 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2010 | 68 | 0.080 |
Why?
|
| Vitamins | 1 | 2010 | 56 | 0.080 |
Why?
|
| Amenorrhea | 1 | 2010 | 2 | 0.080 |
Why?
|
| Overweight | 1 | 2012 | 262 | 0.080 |
Why?
|
| Cell Count | 1 | 2010 | 9 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2010 | 16 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2010 | 12 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 14 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 24 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2011 | 242 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 325 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 110 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 1887 | 0.070 |
Why?
|
| Health Maintenance Organizations | 1 | 2010 | 358 | 0.070 |
Why?
|
| Mice | 3 | 2002 | 59 | 0.070 |
Why?
|
| Anal Canal | 1 | 2006 | 9 | 0.060 |
Why?
|
| Age of Onset | 1 | 2006 | 66 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 67 | 0.060 |
Why?
|
| Cell Migration Inhibition | 1 | 2006 | 1 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 52 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 4 | 0.060 |
Why?
|
| Germany | 2 | 2016 | 12 | 0.060 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2012 | 515 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 30 | 0.060 |
Why?
|
| Antigens, CD20 | 2 | 2020 | 2 | 0.060 |
Why?
|
| Aphasia | 1 | 2005 | 1 | 0.060 |
Why?
|
| Ataxia | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cytarabine | 1 | 2005 | 1 | 0.060 |
Why?
|
| Paresis | 1 | 2005 | 4 | 0.060 |
Why?
|
| Mice, Inbred Strains | 2 | 2002 | 4 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2002 | 10 | 0.060 |
Why?
|
| Molecular Sequence Data | 2 | 2002 | 16 | 0.060 |
Why?
|
| Mitoxantrone | 1 | 2004 | 2 | 0.050 |
Why?
|
| Research Design | 1 | 2006 | 319 | 0.050 |
Why?
|
| Computers, Handheld | 1 | 2024 | 10 | 0.050 |
Why?
|
| Stakeholder Participation | 1 | 2024 | 20 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2005 | 92 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2024 | 63 | 0.050 |
Why?
|
| Periaqueductal Gray | 1 | 2003 | 1 | 0.050 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2003 | 1 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2003 | 2 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2003 | 7 | 0.050 |
Why?
|
| Oxygen | 1 | 2023 | 14 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 10 | 0.050 |
Why?
|
| Placenta | 1 | 2023 | 20 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 37 | 0.050 |
Why?
|
| Population Control | 1 | 2022 | 1 | 0.050 |
Why?
|
| Dysgammaglobulinemia | 1 | 2002 | 1 | 0.050 |
Why?
|
| Th1 Cells | 1 | 2002 | 1 | 0.050 |
Why?
|
| Myelin Proteolipid Protein | 1 | 2002 | 1 | 0.050 |
Why?
|
| Adoptive Transfer | 1 | 2002 | 1 | 0.050 |
Why?
|
| Autoantigens | 1 | 2002 | 2 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2002 | 3 | 0.050 |
Why?
|
| Cell Movement | 1 | 2002 | 4 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2002 | 8 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2002 | 6 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2002 | 16 | 0.050 |
Why?
|
| Interleukin-17 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 18 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2002 | 24 | 0.050 |
Why?
|
| Medicare | 1 | 2023 | 188 | 0.050 |
Why?
|
| Dementia | 1 | 2024 | 137 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 127 | 0.040 |
Why?
|
| Ligands | 1 | 1999 | 5 | 0.040 |
Why?
|
| Epitopes | 1 | 1999 | 4 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 1999 | 11 | 0.040 |
Why?
|
| Geography, Medical | 1 | 2019 | 4 | 0.040 |
Why?
|
| Antirheumatic Agents | 1 | 2019 | 9 | 0.040 |
Why?
|
| HLA-A3 Antigen | 1 | 2019 | 3 | 0.040 |
Why?
|
| HLA-B7 Antigen | 1 | 2019 | 3 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 34 | 0.040 |
Why?
|
| Haplotypes | 1 | 2019 | 29 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 291 | 0.030 |
Why?
|
| Asian Americans | 1 | 2019 | 146 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 209 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2019 | 167 | 0.030 |
Why?
|
| Anemia, Neonatal | 1 | 2014 | 1 | 0.030 |
Why?
|
| Leukocytosis | 1 | 2014 | 5 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2014 | 13 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 17 | 0.030 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2014 | 12 | 0.030 |
Why?
|
| Gestational Age | 1 | 2014 | 118 | 0.030 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2014 | 55 | 0.030 |
Why?
|
| Mothers | 1 | 2014 | 104 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 2 | 0.020 |
Why?
|
| Income | 1 | 2012 | 81 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2012 | 69 | 0.020 |
Why?
|
| Data Collection | 1 | 2012 | 223 | 0.020 |
Why?
|
| Health Services Research | 1 | 2012 | 180 | 0.020 |
Why?
|
| Health Planning | 1 | 2010 | 15 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 37 | 0.020 |
Why?
|
| Poverty | 1 | 2012 | 167 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 207 | 0.020 |
Why?
|
| Gadolinium | 1 | 2008 | 1 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2008 | 3 | 0.020 |
Why?
|
| Remission Induction | 1 | 2008 | 22 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 138 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 374 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2003 | 8 | 0.010 |
Why?
|
| Receptors, Fc | 1 | 2002 | 1 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 6 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2002 | 4 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 16 | 0.010 |
Why?
|
| Autopsy | 1 | 2002 | 16 | 0.010 |
Why?
|
| Inflammation | 1 | 2002 | 56 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 144 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 346 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1999 | 1 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 4 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1999 | 4 | 0.010 |
Why?
|
| Myelin Basic Protein | 1 | 1999 | 5 | 0.010 |
Why?
|